| Original language | English |
|---|---|
| Pages (from-to) | 2444-2446.e2 |
| Journal | Clinical Gastroenterology and Hepatology |
| Volume | 19 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2021 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Clinical Gastroenterology and Hepatology, Vol. 19, No. 11, 11.2021, p. 2444-2446.e2.
Research output: Contribution to journal › Short survey › peer-review
TY - JOUR
T1 - Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes
AU - Ollech, Jacob E.
AU - Avni-Biron, Irit
AU - Glick, Laura
AU - Haider, Haider
AU - Dalal, Sushila R.
AU - Micic, Dejan
AU - Pekow, Joel
AU - Yanai, Henit
AU - Cohen, Russel D.
AU - Dotan, Iris
AU - Rubin, David T.
AU - Sakuraba, Atsushi
N1 - Funding Information: Funding These authors disclose the following: Joel Pekow has received grant support from AbbVie and Takeda, served as a consultant for Veraste, CVS Caremark and is on the advisory board for Takeda, Janssen, and Pfizer. Sushila R. Dalal has served as a consultant for Pfizer and is on the speaker's bureau for AbbVie. Russel D. Cohen is on the speaker's bureau from AbbVie and Takeda. He is a consultant/advisor for AbbVie Laboratories, BM/celgene, Eli Lilly, Gilead Sciences, Janssen, Pfizer, Takeda, UCB Pharma, and received clinical trial support/grants from Abbvie, BMS/Celgene, Boehringer Ingelheim, Crohn's and Colitis Foundation of America, Genentech, Gilead Sciences, Hollister, Medimmune, Mesoblast Ltd, Osiris Therapeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda Pharma, UCB Pharma, and his wife is on the board of directors of Aerpio Therapeutics, Novus Therapeutics, Vital Therapeutics, Inc, and NantKwest. David T. Rubin has received grant support from Takeda; and has served as a consultant for Abbvie, Abgenomics, Allergan Inc, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd, Bristol-Myers Squibb, Celgene Corp/Syneos, Check- cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., InDex Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Materia Prima, Narrow River Mgmt, Pfizer, Prometheus Laboratories,Reistone, Takeda, and Techlab Inc, and he is co-founder of Cornerstones Health, Inc. and GoDuRn, LLC; on the Board of Trustees of the American College of Gastroenterology. The remaining authors disclose no conflicts. Funding Information: Funding These authors disclose the following: Joel Pekow has received grant support from AbbVie and Takeda, served as a consultant for Veraste, CVS Caremark and is on the advisory board for Takeda, Janssen, and Pfizer. Sushila R. Dalal has served as a consultant for Pfizer and is on the speaker's bureau for AbbVie. Russel D. Cohen is on the speaker's bureau from AbbVie and Takeda. He is a consultant/advisor for AbbVie Laboratories, BM/celgene, Eli Lilly, Gilead Sciences, Janssen, Pfizer, Takeda, UCB Pharma, and received clinical trial support/grants from Abbvie, BMS/Celgene, Boehringer Ingelheim, Crohn's and Colitis Foundation of America, Genentech, Gilead Sciences, Hollister, Medimmune, Mesoblast Ltd, Osiris Therapeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda Pharma, UCB Pharma, and his wife is on the board of directors of Aerpio Therapeutics, Novus Therapeutics, Vital Therapeutics, Inc, and NantKwest. David T. Rubin has received grant support from Takeda; and has served as a consultant for Abbvie, Abgenomics, Allergan Inc, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd, Bristol-Myers Squibb, Celgene Corp/Syneos, Check- cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., InDex Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Materia Prima, Narrow River Mgmt, Pfizer, Prometheus Laboratories,Reistone, Takeda, and Techlab Inc, and he is co-founder of Cornerstones Health, Inc. and GoDuRn, LLC; on the Board of Trustees of the American College of Gastroenterology. The remaining authors disclose no conflicts.
PY - 2021/11
Y1 - 2021/11
UR - http://www.scopus.com/inward/record.url?scp=85097456818&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2020.10.035
DO - 10.1016/j.cgh.2020.10.035
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.shortsurvey???
C2 - 33223497
AN - SCOPUS:85097456818
SN - 1542-3565
VL - 19
SP - 2444-2446.e2
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 11
ER -